Company Profile
ALX Oncology Stock Price, News & Analysis
- Ticker:
- ALXO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
2.11 USD (+9.90%)
Close
Last updated: August 6, 2026
240M USD
Market cap
Why the stock is moving
Following the latest company update, “ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update”, ALXO closed up 9.90% at $2.11 on Aug 6, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
CD47-Directed Immuno-Oncology
ALX Oncology develops therapies intended to activate innate and adaptive antitumor immunity. Its lead approach blocks CD47 signaling while seeking to avoid broad binding to healthy cells.
Evorpacept
Evorpacept is a high-affinity CD47 blocker designed for combination with tumor-targeting antibodies and other anticancer medicines. Current development emphasizes HER2-positive cancers and biomarker-selected patients with high CD47 expression.
ALX2004
ALX2004 is a next-generation clinical candidate that expands the company's innate-immunity pipeline beyond evorpacept and is undergoing initial safety evaluation.
Future catalysts
Initial safety data from the Phase 1 study of ALX2004 in the second half of 2026.
Topline data from the Phase 2 ASPEN-09-Breast study of evorpacept in mid-2027.
Recent news
- 01
- 02
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
Source: ALX Oncology
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of ALX Oncology (ALXO)?
ALX Oncology (ALXO) most recently closed at 2.11 USD, a +9.90% move versus the previous session.
What is the market cap of ALX Oncology (ALXO)?
ALX Oncology currently has a market capitalization of 240M USD on BioPharmSignal.
What does ALX Oncology do?
CD47-Directed Immuno-Oncology ALX Oncology develops therapies intended to activate innate and adaptive antitumor immunity. Its lead approach blocks CD47 signaling while seeking to avoid broad binding to healthy cells. Evorpacept Evorpacept is a high-affinity CD47 blocker designed for combination with tumor-targeting antibodies and other anticancer...
On which exchange is ALXO stock listed?
ALX Oncology (ALXO) is associated with NASDAQ, United States, Biopharma.
What is ASPEN-09?
Topline data from the Phase 2 ASPEN-09-Breast study of evorpacept in mid-2027.
Which conditions is ALX Oncology targeting with ASPEN-09?
ALX Oncology is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does ALX Oncology describe recent progress with ASPEN-09?
Topline data from the Phase 2 ASPEN-09-Breast study of evorpacept in mid-2027.
What is evorpacept?
Evorpacept Evorpacept is a high-affinity CD47 blocker designed for combination with tumor-targeting antibodies and other anticancer medicines.